多中心III期头颈部肿瘤试验中计划自适应放疗与剂量绘画的方案依从性
本研究纳入ARTFORCE试验(NCT01504815)全部221例头颈部肿瘤患者,评估多中心III期试验的质量保证与方案依从性。结果显示,随机至实验性放疗(eRT)的患者中64%至少存在一项实验性试验成分的偏离,偏离与治疗机构显著相关(Cramer's V 0.34-0.48),实验性方案依从性与局部区域控制无显著关系(P≥.15)。
要点
- 随机至eRT的患者中64%至少有一项实验性试验成分的方案偏离。
- 方案偏离与治疗机构显著相关,Cramer's V为0.34-0.48。
- eRT内实验性方案依从性与局部区域控制无显著关系(P≥.15)。
核心结论
- 尽管实施了质量保证,试验期间方案偏离仍持续存在,且多与治疗机构相关。
- 实验性治疗策略的偏离未显著影响局部区域控制,因此未影响试验结论。
研究设计与样本
- 研究纳入ARTFORCE试验(NCT01504815)全部221例头颈部肿瘤患者。
- 治疗前及治疗中质量保证措施包括方案指南、模拟运行、早期病例审查和试验会议。
- 对实验组(eRT)患者的FDG-PET引导剂量绘画和计划自适应放疗进行审查。
- 采用Cox回归分析方案依从性对结局的影响。
主要发现
- 模拟运行在全部9个机构完成,早期病例审查在9个机构中的5个完成,这5个机构贡献了221例中的190例患者。
- 随机至eRT的患者中,64%至少存在一项实验性试验成分的偏离。
- 方案偏离与患者接受治疗的机构显著相关(Cramer's V 0.34-0.48)。
- 偏离与入组时间或入组速率无显著关联(P ≥ 0.26)。
- eRT内实验性方案依从性与局部区域控制(LRC,试验主要终点)无显著关系(P≥.15)。
关键数值与推荐
- 随机至eRT的患者中64%至少存在一项实验性试验成分的偏离。
- 方案偏离与治疗机构的Cramer's V为0.34-0.48。
- 偏离与入组时间或速率的关联P ≥ 0.26。
- eRT内实验性方案依从性与LRC的关联P≥.15。
局限性
- 早期病例审查仅在9个机构中的5个完成,这5个机构贡献了221例中的190例患者。
- 尽管质量保证中早期识别了机构特异性偏离,这些偏离在试验期间仍持续存在。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report on quality assurance (QA) and protocol adherence (PA) in a multicentre phase III trial for head and neck cancer, evaluate patterns of protocol deviations and investigate the effect of PA on study outcomes. METHODS: All 221 patients from the ARTFORCE trial (NCT01504815) were included in this study. Pre- and per-treatment QA measures included protocol guidelines, a dummy run, early case reviews and trial meetings. FDG-PET-guided dose painting and scheduled adaptive radiotherapy were reviewed in patients in the experimental arm (eRT). Patient and disease characteristics, as well as institutes' accrual rate and timing were examined for correlation with PA. Cox regression was used to determine the impact of PA on outcome. RESULTS: The dummy run was completed in all nine institutes and early case reviews were completed in five out of nine institutes that contributed 190 out of 221 patients. Among all patients randomized to eRT, 64 % had at least one deviation of the experimental trial components. Protocol deviations were significantly correlated with the institute patients were treated at (Cramer'sV 0.34-0.48). Despite early identification of institute-specific deviations in QA, these continued during the trial. No significant associations were seen between deviations and accrual timing or rate (P ≥ 0.26). Within eRT, no significant relation was observed between experimental PA and locoregional control (LRC), the primary endpoint of the trial (P≥.15). CONCLUSIONS: Despite QA, protocol deviations persisted during the trial, which were mostly institute-specific. However, deviations of the experimental treatment strategy did not significantly impact LRC and therefore the trial conclusion.
引用
- de Leeuw ALMP, Giralt J, Tao Y, et al. Protocol compliance in a multicentric phase III trial investigating scheduled adaptive radiotherapy and dose painting in head and neck cancer. Radiother Oncol. 2024. PMID: 39522824. doi:10.1016/j.radonc.2024.110612
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。